“Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 2 Trial”, J of Skin, vol. 9, no. 6, p. s692, Nov. 2025, doi: 10.25251/w6str133.